DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) today announced a PER.C6® license agreement with biopharmaceutical
company Medarex, Inc.
DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products,
announced today that they have entered into an enzyme supply agreement with
the German company IEP to enable fast and secure scale-up of chiral alcohol
manufacturing based on IEP enzymes.
DSM's Greenville North Carolina site was honored Thursday, November 15th as
the recipient of the 2007 North Carolina International Community and Economic
Development Award. The award is given by the N.C. Department of Commerce in
recognition of the important civic and philanthropic contributions made by
foreign-owned businesses.
DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) today announced a PER.C6® license agreement with Daiichi Sankyo Ltd.
DSM Pharmaceuticals Inc., a leading global supplier of pharmaceutical
manufacturing services, announces today that they have expanded their service
offerings to include Formulation Development and Clinical Trial Manufacturing
for solid dosage form products.
DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) today announced that they have signed a non-exclusive PER.C6® technology
research licensing agreement with Brazilian-based Recepta Biopharma S.A.
DSM Pharmaceutical Products, a leading provider of contract development and
manufacturing services is pleased to announce today DSM has been awarded the
Silver, CPhI Innovation Award. DSM Pharmaceutical Products has won the Silver
Award for their work on the use of MonoPhos™ ligands in asymmetric
hydrogenations.
DSM Biologics, a business unit of DSM Pharmaceutical Products and Crucell
have signed a Biopharmaceutical Manufacturing Agreement for production on the
basis of the PER.C6® manufacturing platform of Crucell’s proprietary antibody
cocktail (containing two antibodies), which Crucell develops against rabies.
DSM Pharmaceuticals Inc., a leading global provider of aseptic manufacturing
and development services to the pharmaceutical and biopharmaceutical
industries, announces today the addition of aseptic fill-finish manufacturing
services for injectable cytotoxic products.
DSM Pharmaceutical Products, a leading provider of contract development and
manufacturing services is pleased to announce today their nomination to
receive the CPhI Innovation Award. DSM has been nominated for their work on
the use of MonoPhos™ ligands in asymmetric hydrogenations.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has participated in an equity investment round in the Danish company
Upfront Chromatography, the world's leading developer of customized industrial
protein chromatography processes.
DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) today announced a non-exclusive PER.C6® research licensing agreement with
Paris, France-based LFB Biotechnologies.
Royal DSM N.V. and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ:
CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research
licensing agreement with Moscow, Russia-based Masterclone.
DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) today announced a non-exclusive PER.C6® research licensing deal with
Goettingen, Germany-based Sartorius Biotech GmbH.
DSM Pharmaceuticals Inc., a leading provider of contract development and
manufacturing services, is pleased to announce that Mr. Joseph Marchese has
joined the company as Senior Director, Business Manager, Sterile Injectables.
Prior to joining DSM, Mr. Marchese was Vice President Sales and Marketing at
West-Ward Pharmaceutical Corp.
DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) today announced that they have signed a non-exclusive PER.C6® research
licensing deal with Taipei, Taiwan-headquartered Development Center for
Biotechnology (DCB).
Royal DSM N.V. and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX),
today announce fermentation yields of more than 10 grams per liter for
monoclonal antibodies, a major breakthrough in the development of their PER.C6
technology platform.
DSM Biologics, a business unit of DSM Pharmaceuticals, and Dutch biotechnology
company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced
today that they have further intensified their PER.C6® collaboration, by
executing an agreement to expand the existing commercial relationship to
include new classes of proteins, including biosimilar protein products.
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss
Exchange: CRX) and technology partner DSM Biologics today announced that they
have signed a PER.C6® research license agreement with the Taiwan-based
AbGenomics Corporation.
DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch
biotechnology partner Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) announced today that they have signed a PER.C6® license agreement with
pioneering and leading Portuguese biotechnology company, Biotecnol SA, and its
USA based subsidiary Biotecnol, Inc.
DSM Pharmaceuticals recently completed an expansion to its sterile parenteral
manufacturing facility in Greenville, NC, adding a Clinical Trial Material
manufacturing suite capable of manufacturing large and small molecule liquid
and lyophilized products for PI-III clinical trials.
